A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

The film gives the main points. The full list below is copied from the registry; the study team makes the final decision.

• Age18 Years to no maximum
• SexAll
• Healthy volunteersNo

You may be able to join if

• Diagnosis of histologically or cytologically confirmed extensive stage small cell lung cancer (ES-SCLC) requiring treatment with first line therapy.
• Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 during the screening period prior to the first dose of study treatment.
• Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
• Suspected brain metastases at screening should have a computed tomography (CT)/ magnetic resonance imaging (MRI) of the brain prior to study entry.

You cannot join if

• Have received any kind of treatment for limited stage small cell lung cancer (LS-SCLC).
• Known active/symptomatic central nervous system (CNS) metastases should be excluded.
• History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD/pneumonitis on screening chest computed tomography (CT) scan should be excluded.
• Have any clinically significant conditions that would adversely affect the participant's participation in the study, and the subject should have a life expectancy of at least 3 months.

This is how the treatment is meant to work. Whether it helps, and how safe it is, is what this trial is testing.

anti-SEZ6 antibody-drug conjugate ABBV-706. An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against seizure protein 6 homolog (SEZ6) linked to an undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration of anti-SEZ6 ADC ABBV-706, the monoclonal antibody moiety targets and binds to SEZ6 expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills SEZ6-expressing tumor cells through an as of yet undisclosed mechanism. SEZ6, overexpressed in certain cancers while minimally expressed in normal tissues, may play a role in cell-cell recognition and in neuronal membrane signaling. NCI Drug Dictionary

atezolizumab. A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). NCI Drug Dictionary

Treatments listed in the registry

• ABBV-706 (Drug): Intravenous (IV) Infusion
• Atezolizumab (Drug): IV Infusion
• Etoposide (Drug): IV Infusion
• Carboplatin (Drug): IV Injection
• Carboplatin (Drug): IV Infusion
• Lurbinectedin (Drug): IV Infusion

Randomized · Sequential · masking: None

Main goals

• Number of Participants with Adverse Events (AE)s (Up to 69.5 Months)
• Progression-Free Survival (PFS) Based on Investigator Assessment (Up to Approximately 24 Months)

Other goals

• Overall Response (OR) as Measured by Overall Response Rate (ORR) Based on Investigator Assessment
• Duration of Response (DoR) Based on Investigator Assessment
• Disease Control (DC) Based on Investigator Assessment
• OS

Planned enrollment: 180 (estimated).

• Yale University School of Medicine /ID# 278181, New Haven, Connecticut
• University of Florida College of Medicine /ID# 277496, Gainesville, Florida
• Ocala Oncology Center /ID# 278269, Ocala, Florida
• Moffitt Cancer Center /ID# 277573, Tampa, Florida
• Fort Wayne Medical Oncology And Hematology /ID# 277336, Fort Wayne, Indiana
• Baptist Health Lexington /ID# 277729, Lexington, Kentucky
• Dana-Farber Cancer Institute /ID# 277732, Boston, Massachusetts
• Henry Ford Hospital - Detroit /ID# 277218, Detroit, Michigan
• Missouri Cancer Associates /ID# 278299, Columbia, Missouri
• University Hospitals Cleveland Medical Center /ID# 277556, Cleveland, Ohio
• The University of Texas MD Anderson Cancer Center /ID# 277929, Houston, Texas
• Virginia Cancer Specialists - Fairfax /ID# 278298, Fairfax, Virginia

58 recruiting sites outside the US. Site status as of Oct 30, 2026. Check the live record before contacting a site.

• ClinicalTrials.gov NCT07155174
• NCI Drug Dictionary: C198215
• NCI Drug Dictionary: C106250

Registry record reviewed as fetched Oct 30, 2026, last updated by the sponsor Oct 26, 2026. Public record; not medical advice.